MEDAMACS 1-YEAR STUDY RESULTS ON ADVANCED HEART FAILURE INDICATE CLINICIANS SHOULD EXPAND VAD THERAPY TO THOSE PREVIOUSLY THOUGHT AS ‘TOO HEALTHY’ San Diego, April 08, 2017 (GLOBE NEWSWIRE) -- Today researchers presented findings of the Medical Arm of Mechanically Assisted Circulatory Support (MedaMACS) study, a multi-center, U.S.-based study,...

ENDURANCE SUPPLEMENTAL ONE-YEAR HVAD RESULTS SHOW DECREASED RATE OF STROKE COMPARED TO ENDURANCE TRIAL San Diego, April 05, 2017 (GLOBE NEWSWIRE) -- Today, during the opening plenary session of the 37TH Annual International Society for Heart and Lung Transplantation (ISHLT) Meeting & Scientific...

Improved Outcomes Using Mesoblast Cells in End-Stage Heart Failure NEW YORK and MELBOURNE, Australia, June 24, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today announced that trial results evaluating a low dose...